v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Net cash flows from operating activities:    
Net (loss) income $ (20,019) $ 7,342
Adjustments to reconcile net (loss) income to net cash from operating activities:    
Depreciation and amortization 20,432 16,701
Non-cash compensation 22,802 20,302
Non-cash lease expense 3,968 3,824
Write-down of inventories and deferred preservation costs 3,765 3,779
Deferred income taxes (835) (1,484)
Change in fair value of contingent consideration 13,738 2,390
Losses on inducement/extinguishment of debt 0 2,664
Gain from sale of non-financial assets 0 (3,500)
Other (2,089) (7,315)
Changes in operating assets and liabilities, net of acquisition:    
Receivables (4,038) (924)
Inventories and deferred preservation costs (16,409) (11,563)
Prepaid expenses and other assets (4,511) (4,703)
Accounts payable, accrued expenses, and other liabilities (21,472) (7,193)
Net cash flows (used in) provided by operating activities (4,668) 20,320
Net cash flows from investing activities:    
Capital expenditures (31,764) (11,534)
Acquisition of Endospan, net of cash acquired (116,661) 0
Payments related to sale of non-financial assets (1,500) 0
Other (3,000) 0
Net cash flows used in investing activities (152,925) (11,534)
Net cash flows from financing activities:    
Proceeds from issuance of long-term debt, net 148,875 0
Repayment of debt 0 (207)
Proceeds from exercise of stock options and issuance of common stock 4,121 9,613
Payment of debt issuance costs 0 (1,750)
Proceeds from financing insurance premiums 3,217 3,117
Principal payments on short-term notes payable (2,309) (1,395)
Payment of contingent consideration (11,686) 0
Other (648) (526)
Net cash flows provided by financing activities 141,570 8,852
Effect of exchange rate changes on cash and cash equivalents (486) 2,325
(Decrease) increase in cash and cash equivalents (16,509) 19,963
Cash and cash equivalents beginning of period 64,908 53,463
Cash and cash equivalents end of period $ 48,399 $ 73,426